Chronic Lymphocytic Leukemia (CLL) research hub
7 indexed studies · 5 currently recruiting
- ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation
This study compares two treatments for newly diagnosed Chronic Lymphocytic Leukemia (CLL). It looks at how well a combination of venetoclax and obinutuzumab works against standard treatments (FCR/BR) to reduce tiny amounts of cancer cells and improve overall health.
Spain · France · Italy - recruitingPHASE2
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
This study looks at a new way to re-treat a type of blood cancer called CLL when it returns. It uses two approved medicines, venetoclax and obinutuzumab, in adults who have had previous venetoclax treatment.
United States · Australia · Austria - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and Chlorambucil in Previously Untreated Patients with CLL and Coexisting Medical Conditions
This study compares two treatments for chronic lymphocytic leukaemia (CLL) in patients who haven't had treatment before and have other health issues. It's looking at how well a new combination of medicines works against a standard treatment, aiming to find safer and more effective options.
Bulgaria · Estonia · Romania - recruitingPHASE2
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
This study looks at a new drug, NX-5948, for adults with specific types of blood cancer (CLL or SLL) that have come back or not responded to previous treatments. It aims to see how well and how safely this new drug works.
United States · France · Italy - recruitingPHASE1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
This study is testing a new medicine, NX-5948, for adults with certain types of blood cancer that have come back or not responded well to previous treatments. It aims to find out if the medicine is safe and helps fight the cancer, starting with small doses and gradually increasing.
United States · France · Italy - recruiting
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
This study looks at how a medicine called venetoclax works for people with a type of blood cancer called Chronic Lymphocytic Leukemia (CLL) in everyday medical care. Researchers will check its effects, costs, and how patients feel while taking it, either alone or with other common treatments.
Austria · Germany · Switzerland - recruiting
Observational Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukaemia in the United Kingdom
This study looks back at how well a medicine called acalabrutinib worked for people in the UK with Chronic Lymphocytic Leukaemia (CLL) who took it first, as part of an early access programme. Researchers want to understand their experiences and treatment outcomes in real life.
United Kingdom